

Form 8.1 – Covidien

DUBLIN, Ireland--(BUSINESS WIRE)--Oct. 8, 2014-- Covidien plc:

FORM 8.1(a)&(b)(i)

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1. KEY INFORMATION

Name of person dealing (Note 1)	Jose E Almeida
Company dealt in	Covidien plc
Class of relevant security to which the dealings being disclosed relate (Note 2)	Ordinary Shares
Date of dealing	3 Oct 2014 and 18 Aug 2014

2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long Number	Short Number	
	(%)	(%)	
(1) Relevant securities	354,242	0.08%	
(2) Derivatives (other than options)			
(3) Options and agreements to purchase/sell	1,087,026	0.23%	
Total	1,441,268	0.31%	

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:	Long Number (%)	Short Number (%)
(1) Relevant securities		
(2) Derivatives (other than options)		
(3) Options and agreements to purchase/sell		
Total		

3. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (Note 5)
Sale (Redemption by Covidien plc)	58,376	US\$93.89
Credit of Dividend Equivalent Units	852	N/A

(b) Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)
------------------------	--------------------------------	----------------------------------------	-------------------------

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)
--------------------------------	--------------------------------------------	-----------------------------------------------------------	----------------	------------------------------------	-------------	----------------------------------------------

(ii) Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)
Performance Share Units (Vesting)	123,676	US\$0.20

(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Price per unit Details (if applicable) (Note 5)
--------------------------------	----------------------------------------------------

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None

Is a Supplemental Form 8 attached? (Note 9)	NO
Date of disclosure	8 October 2014
Contact name	Lisa Clemence
Telephone number	+1 508-452-4375
Name of offeree/offeror with which acting in concert	Covidien plc
Specify category and nature of acting in concert status	Director of Covidien plc

A person interested in 1% or more of any relevant securities in the Covidien plc (the "Company") may have disclosure obligations under Rule 8.3 of the Irish Takeover Rules. This requirement will continue until the offer period ends.

The directors of the Company accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the directors (who have taken all reasonable care to ensure that such is the case) the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Source: Covidien plc

Covidien

Peter Lucht, 508-452-4168

Vice President

External Communications

peter.lucht@covidien.com

or

Lisa Clemence, 508-452-4375

Director

Corporate Communications

lisa.clemence@covidien.com

or

Coleman Lannum, CFA, 508-452-4343

Vice President

Investor Relations

cole.lannum@covidien.com

or

Todd Carpenter, 508-452-4363

Senior Director

Investor Relations

todd.carpenter@covidien.com

<https://news.medtronic.com/2014-10-08-Form-8-1-Covidien>